Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which the body's immune system erroneously attacks its own tissues, causing inflammation in various organs and tissues.
The disease course is characterized by a relapsing-remitting pattern, with periods of remission (when the disease subsides) and exacerbation (when the disease worsens). The current primary treatment involves the administration of steroids and immunosuppressants; however, in over half of patients, exacerbations cannot be entirely prevented.
Furthermore, as the medication dosage increases to suppress disease symptoms, the risk of serious adverse effects, such as severe infections, also rises. Long-term steroid use leads to adverse effects (e.g., osteoporosis, diabetes, severe infections) that significantly impact patients' quality of life.
Furthermore, among the novel biological therapies for SLE that have recently emerged, only one (belimumab) has received US FDA approval in recent decades. Even this therapy, however, is not sufficiently effective for all patients.
Consequently, current treatments for SLE are limited in terms of both efficacy and associated adverse effects. Patients are therefore seeking novel therapeutic approaches that are safer and more fundamental.
Systemic Lupus Erythematosus and Stem Cell Therapy: New Possibilities in Regenerative Medicine
Whereas conventional pharmacotherapy focuses on 'suppressing' symptoms, stem cell therapy, through regenerative medicine, is a novel approach that aims to 'repair and normalize' the body's own functions.
In autoimmune diseases such as Systemic Lupus Erythematosus (SLE), the immune system, which is designed to defend the body, becomes dysfunctional and attacks itself. Stem cell therapy holds the potential to reset these abnormal immune reactions and restore the body to a normal state.
Specifically, a type of stem cell known as mesenchymal stem cells (MSCs) has garnered particular attention, with research and clinical trials currently underway worldwide. MSCs can be harvested from bone marrow, adipose tissue, umbilical cord, and other sources, with the option of using the patient's own cells (autologous) or cells from a donor (allogeneic).
Among these, Wharton's Jelly-derived stem cells (WJ-MSCs), contained within the umbilical cord, are considered highly promising. Wharton's Jelly is a gelatinous tissue within the umbilical cord, obtained at birth.
MSCs derived from this section are reported to be less frequently rejected by the immune system compared to bone marrow-derived MSCs, and possess a high proliferative capacity. Consequently, it is anticipated that a large number of stem cells can be provided with minimal burden, and are expected to be suitable for administration to patients.
Stem cell therapy is at the forefront of regenerative medicine, bringing new hope even for refractory Systemic Lupus Erythematosus (SLE) (cases unresponsive to conventional therapies) that previously lacked effective treatment options.
Mechanism of Action of Stem Cell Therapy for Systemic Lupus Erythematosus
Mesenchymal Stem Cells (MSCs) are considered effective for Systemic Lupus Erythematosus (SLE) due to their ability to address the disease's pathophysiology through multiple mechanisms. We will outline three key mechanisms by which stem cell therapy functions in SLE.
Immunomodulatory action (recalibration)
MSC modulates an overactive immune system and restores equilibrium. MSCs are understood to interact with the immune system's 'command center,' effectively re-educating it to cease targeting the body's own tissues.
Specifically, MSC promotes the expansion of regulatory T cells (Tregs) that suppress excessive self-reactivity, and inhibits the aberrant activation of autoantibody-producing B cells. In this manner, MSC curbs immune dysregulation.
Anti-inflammatory activity and tissue repair.
MSCs release numerous active substances and small secretory vesicles, collectively referred to as the "secretome." These substances act systemically to mitigate inflammation and promote the repair of damaged tissue.
For instance, by mitigating inflammatory triggers and simultaneously providing growth factors that facilitate tissue repair and regeneration, the aim is to bolster the regenerative potential of damaged organs.
Organ protection and function
SLE frequently causes damage to vital organs such as the kidneys and lungs. MSCs attenuate the assault on these organs and serve to arrest damage. Indeed, in animal models and preliminary studies, MSC administration has improved indicators of renal function and histologically reduced organ tissue damage.
Stem cell therapy represents a comprehensive 'curative' and 'controlling' approach that impacts the pathophysiology of SLE from multiple angles. In essence, it is a treatment method designed to modulate the dysregulated immune system while facilitating the repair of damaged tissues. While research is ongoing to elucidate more detailed mechanisms, patients anticipate this as a 'treatment that enhances systemic well-being and addresses the root cause of the disease'.
Evidence of the Effectiveness of Stem Cell Therapy for Systemic Lupus Erythematosus
What is the actual efficacy of stem cell therapy? To date, small-scale clinical trials and patient series reports have been conducted globally, with the majority indicating promising outcomes. The following provides some evidence.
Clinical Trial of Umbilical MSC Transplantation in 15 Refractory SLE Patients (China)
A study investigated the intravenous administration of allogeneic WJ-MSCs to 15 Systemic Lupus Erythematosus (SLE) patients presenting with high disease activity and an inadequate response to conventional therapy. Approximately one year post-administration, results indicated a significant increase in disease activity across all patients, accompanied by a decline in organ damage indicators, including renal function.
It is important to note that no serious adverse events were reported. Although some patients experienced a recurrence of renal damage (proteinuria) one year after treatment initiation, the majority of patients were able to maintain a state of remission.
Long-term Follow-up Results of MSC Therapy (6 Years)
A 6-year follow-up report on a subset of patients (which overlapped with the aforementioned report) indicated that all patients tolerated the treatment well, and in the long term, there was no increased risk of developing cancer or serious infections.
Reports indicated a sustained decrease in disease activity indicators (SLEDAI scores) attributable to the treatment, with the reduction of autoantibodies and improvement in renal function being maintained. This finding, demonstrating the long-term preservation of both safety and efficacy, constitutes significant evidence that enhances confidence in stem cell therapy.
Phase I Clinical Trial in the United States (Supported by LFA)
WJ-MSC Phase I clinical trials have also yielded promising results, supported by the Lupus Foundation of America (LFA) and the National Institutes of Health (NIH).
In this trial, disease activity markedly decreased in 5 out of 6 refractory SLE patients following MSC administration, with effects persisting for one year. Additionally, successful steroid dose reduction was achieved (5 out of 6 patients successfully reduced steroids to 10 mg/day or less).
Regarding safety, no significant issues were identified, with only mild nausea and mild perspiration observed in a few patients. Based on these findings, a Phase II clinical trial targeting a larger patient cohort is underway.
In addition to this research, reports on the use of Mesenchymal Stem Cells (MSCs) continue to emerge globally, and experts have evaluated that "MSC therapy is a promising therapeutic approach that may be effective for Systemic Lupus Erythematosus (SLE) refractory to conventional treatment."
Certainly, it remains in the clinical trial phase and cannot yet be considered an established standard treatment. However, the currently available evidence strongly suggests the efficacy of stem cell therapy.
Notably, beneficial findings directly associated with patients' long-term prognosis, such as the improvement of renal lesions and steroid-sparing effects, must not be overlooked.
Safety of Stem Cell Therapy for Systemic Lupus Erythematosus and Side Effects
When considering a new treatment, "safety" is a primary concern for patients and their families.
Although stem cell therapy has not yet been established as a covered treatment, based on accumulated clinical research, it is reported to possess a relatively high safety profile.
As detailed above, clinical trials revealed no serious side effects or virtually any complications. In trials conducted in the United States, only mild nausea and hot flashes were observed, and long-term studies in China showed no increased risk of cancer development or serious infections.
When utilizing autologous stem cells, rejection is not a concern. Even with allogeneic cells, serious rejection issues are uncommon. Furthermore, the use of stem cells derived from birth byproducts, such as WJ-MSCs, involves no donor invasion and presents minimal ethical barriers.
For these reasons, ongoing clinical trials have reported no major safety concerns regarding the safety of stem cell therapy, and patients can therefore approach it with confidence.
This high safety profile is one reason for optimism about stem cell therapy.
Conclusion
Stem cell therapy for Systemic Lupus Erythematosus is an area within regenerative medicine research that is currently receiving particular attention.
When conventionally intractable cases are illuminated by an approach that targets the body's intrinsic constitution, aiming for fundamental improvement, and is substantiated by extensive clinical trials and research.
Certainly, extensive research and time are still necessary before it can be established as a standard treatment. However, the progressively accumulating knowledge, both domestically and internationally, indicates substantial progress.
For patients and families living with SLE, the emergence of stem cell therapy as a new option offers significant promise. In the future of medicine, the body's inherent repair agents—stem cells—could potentially repair parts damaged by the disease and guide the dysregulated immune system back to normalcy, making such treatments a routine practice.
We are steadily advancing towards that day, and the avenue of hope for stem cell therapy will undoubtedly open.
Medical professionals and researchers are diligently working together towards a future where patients can confidently access these benefits. We encourage you to anticipate future developments with optimism.
For inquiries concerning stem cell therapy or treatment options, please consult thoroughly with your treating physician. We hope you receive a comprehensive explanation of the most appropriate options, informed by the latest research trends.